Emergent BioSolutions reported $-148.1M in EBIT for its fiscal quarter ending in March of 2023.





Ebit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Exelixis USD 268.42M 20.01M Sep/2026
Glaxosmithkline GBP 2.15B 157M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Lonza CHF 673M 54M Jun/2025
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pacira USD 2.57B 2.56B Sep/2026
Pfizer USD 4.85B 5.03B Sep/2026
PTC Therapeutics USD 146.03M 100.14M Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
United Therapeutics USD 241.3M 134.3M Sep/2026
Vanda Pharmaceuticals USD -10.28M 721K Dec/2024